A Phase 2 Study of Poziotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Exon 20 Mutation in China and Korea
Latest Information Update: 04 Nov 2021
Price :
$35 *
At a glance
- Drugs Poziotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Hanmi Pharmaceutical
- 16 Nov 2020 Status changed from active, no longer recruiting to discontinued by the Sponsor.
- 07 Aug 2020 Planned End Date changed from 7 Apr 2022 to 1 Aug 2020.
- 07 Aug 2020 Planned primary completion date changed from 30 Jun 2021 to 1 Aug 2020.